EPS for Amphastar Pharmaceuticals, Inc. (AMPH) Expected At $-0.04

March 11, 2018 - By Vivian Park

 EPS for Amphastar Pharmaceuticals, Inc. (AMPH) Expected At $ 0.04
Investors sentiment increased to 0.91 in Q3 2017. Its up 0.15, from 0.76 in 2017Q2. It increased, as 11 investors sold Amphastar Pharmaceuticals, Inc. shares while 32 reduced holdings. 10 funds opened positions while 29 raised stakes. 20.04 million shares or 0.68% less from 20.18 million shares in 2017Q2 were reported.
Ameriprise Financial holds 184,260 shares or 0% of its portfolio. New York-based Ny State Teachers Retirement System has invested 0% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Geode Cap Management Limited Com holds 327,389 shares. State Street Corporation stated it has 0% of its portfolio in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Ls Inv Advisors Ltd Liability Corp invested in 1,485 shares. Bnp Paribas Arbitrage Sa owns 17,946 shares for 0% of their portfolio. Rothschild Asset Management stated it has 354,053 shares or 0.07% of all its holdings. Texas Permanent School Fund owns 25,968 shares. California State Teachers Retirement Sys holds 58,013 shares. Sg Americas Secs Llc reported 0% of its portfolio in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Northern Tru Corporation reported 0% of its portfolio in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Winslow Evans & Crocker accumulated 1,758 shares or 0.01% of the stock. Gsa Capital Ltd Liability Partnership holds 0.03% or 22,400 shares in its portfolio. Manufacturers Life Insur Co The holds 0% of its portfolio in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) for 28,588 shares. State Of Wisconsin Inv Board has 0% invested in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) for 28,000 shares.

Analysts expect Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) to report $-0.04 EPS on March, 12.They anticipate $0.02 EPS change or 33.33 % from last quarter’s $-0.06 EPS. After having $0.07 EPS previously, Amphastar Pharmaceuticals, Inc.’s analysts see -157.14 % EPS growth. The stock increased 1.81% or $0.34 during the last trading session, reaching $19.14. About 300,314 shares traded or 58.95% up from the average. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has risen 8.19% since March 11, 2017 and is uptrending. It has underperformed by 8.51% the S&P500.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Ratings Coverage

Among 6 analysts covering Amphastar Pharmaceuticals (NASDAQ:AMPH), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Amphastar Pharmaceuticals had 26 analyst reports since August 10, 2015 according to SRatingsIntel. On Monday, July 17 the stock rating was maintained by Jefferies with “Buy”. On Wednesday, June 29 the stock rating was initiated by BMO Capital Markets with “Market Perform”. As per Tuesday, May 10, the company rating was maintained by Needham. The company was maintained on Tuesday, January 19 by Jefferies. Zacks downgraded Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) on Monday, August 10 to “Buy” rating. The rating was maintained by BMO Capital Markets with “Hold” on Thursday, October 26. The firm has “Outperform” rating by Wells Fargo given on Friday, February 19. The rating was upgraded by Zacks on Tuesday, August 18 to “Hold”. The rating was maintained by Piper Jaffray with “Buy” on Friday, July 28. Raymond James downgraded Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) on Tuesday, March 14 to “Outperform” rating.

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products. The company has market cap of $879.98 million. It operates in two divisions, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. It currently has negative earnings. The company's product portfolio comprises enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; naloxone for treating opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures.

More important recent Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) news were published by: Reuters.com which released: “US jury sides with Amphastar over Momenta in drug patent trial” on July 21, 2017, also Globenewswire.com published article titled: “Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold …”, Globenewswire.com published: “Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold …” on March 05, 2018. More interesting news about Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) was released by: Globenewswire.com and their article: “Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended …” with publication date: May 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.